Delix Zalsupindole Phase 1b Results

Delix Therapeutics presented positive Phase 1b clinical trial data for its novel neuroplastogen, Zalsupindole (DLX-001), at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference. The study, conducted on 18 adults with Major depressive disorder, utilized Cumulus Neuroscience's NeuLogiq Platform to assess safety, efficacy, and neuroplasticity biomarkers. Key findings indicated that Zalsupindole did not cause psychotomimetic, hallucinatory, dissociative, or cognitive impairment effects, which is a significant differentiator from other plastogens requiring clinical observation. This data supports the feasibility of at-home administration for Zalsupindole in future trials, including an upcoming placebo-controlled Phase 2 study. The NeuLogiq Platform also detected a pharmacodynamic signal consistent with previous Phase 1 healthy volunteer studies. This advancement is crucial for addressing the unmet needs in Major depressive disorder treatment, offering a potentially faster, stronger, and more effective outpatient pharmacotherapy.